Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Next Previous
Search
Trial Profile

Phase II Study of Alisertib as a Single Agent in Recurrent and Refractory Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Etoposide; Methotrexate; Pegfilgrastim; Topotecan; Vincristine
  • Indications Rhabdoid tumour; Teratoma
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms SJATRT

    • Most Recent Events

    • 27 Feb 2023 Planned End Date changed from 1 May 2027 to 1 Sep 2027.
    • 27 Feb 2023 Planned primary completion date changed from 1 May 2025 to 1 Sep 2025.
    • 27 Feb 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top